Loading
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Previous close
$7.45
+$0.14 · +1.92%
After-hours
$7.38
−$0.07 · -0.94%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Day range
Current $7.45
52-week range
Current $7.45
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
61
Undervalued
Sentiment
63
Bullish
Risk
66
High Risk
Momentum
25
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Day range
Current $7.45
52-week range
Current $7.45
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 262.6M USD | 263.4M USD | 78.5M USD | 131.4M USD | 53.6M USD |
| Cost of goods sold | 5.2M USD | — | — | — | — |
| Gross profit | 257.4M USD | 263.4M USD | 78.5M USD | 131.4M USD | 53.6M USD |
| Research and development | 282.9M USD | 348.2M USD | 379.7M USD | 315M USD | 180.4M USD |
| Selling, general, and administrative | 89.4M USD | 165.4M USD | 100.3M USD | 79.6M USD | 61.6M USD |
| Operating expenses | 372.3M USD | 513.6M USD | 480M USD | 394.6M USD | 242M USD |
| Interest income | 22M USD | 54.8M USD | 38.8M USD | 12M USD | 1.8M USD |
| Interest expense | — | — | — | — | 100K USD |
| Depreciation and amortization | 5.2M USD | 6.6M USD | 6.7M USD | 8.2M USD | 6M USD |
| Operating income | −114.9M USD | −250.2M USD | −401.5M USD | −263.2M USD | −188.4M USD |
| Net income | −80.8M USD | −198.9M USD | −367.3M USD | −282.5M USD | −191M USD |
Company facts updated Oct 8, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI17.67M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM11.49M0.01%78.56B USD0.19%$277.7-1.29%
Vanguard Extended Market ETFVXF6.93M0.01%95.4B USD0.05%$233.49-1.56%
State Street SPDR S&P Pharmaceuticals ETFXPH3.58M0.73%462.1M USD0.35%$62.910.00%
Fidelity Enhanced Small Cap ETFFESM3.39M0.05%6.41B USD0.28%$45.22-1.14%
iShares Biotechnology ETFIBB3.24M0.03%10.4B USD0.44%$203.34+0.12%
Vanguard Russell 2000 ETFVTWO3.14M0.02%18B USD0.06%$112.21-1.26%
Schwab U.S. Small-Cap ETFSCHA2.26M0.01%22.01B USD0.03%$32.61-1.47%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFState Street SPDR S&P Pharmaceuticals ETFXPHFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
